Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOVA-HIV: Reduced Dosing of 9vHPV Vaccine in WLWH
NCT05495906Phase 4Recruiting
- Sponsor
- University of British Columbia
- Start
- Jul 2023
- Primary completion
- Aug 2026
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 4 trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, Cervical Cancer (CC), sponsored by University of British Columbia. Started Jul 2023; status: recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infectionCervical Cancer (CC)
Beyond the preview
Go deeper on NCT05495906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05495906.